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The in-vitro, experimental and clinical activities of spiramycin against Toxoplasma 
gondii have been reviewed. In mammalian cells infected by T. gondii as in various 
experimental models, spiramycin definitively exerts an inhibitory antitoxoplasmic 
effect which, clinically, seems useful for preventing congenital toxoplasma infection 
during pregnancy or for reducing the inflammation in toxoplasmic chorioretinitis. 
However, spiramycin does not kill the parasite efficiently, and cannot be 
recommended for eradicating the most severe forms of toxoplasmosis. 
Introduction 
Infections due to the intracellular protozoan parasite Toxoplasma gondii are frequent 
among animals and man all over the world. Fortunately, only a small percentage of 
those infections produce toxoplasmosis. Exceptions are acute infections in pregnant 
women, chorioretinitis and recrudescences in immunocompromised hosts which cause 
major concerns because they can lead to dramatic sequelae or life-threatening 
toxoplasmosis. The infected fetus often develops serious sequelae such as impaired 
vision or neurological disorders, even after five years post-partum (Koppe, Loewer-
Sieger & De Roever-Bonnet, 1986). AIDS patients have a striking propensity for the 
development of a life-threatening infection such as toxoplasmic encephalitis. 
Current therapy with the combination of pyrimethamine and sulphadiazine (or triple 
sulphonamides) (Eyles & Coleman, 1955) has the disadvantage of producing many 
adverse and even toxic effects (Kutscher, Lane & Segael, 1954; Kaufman & Geisler, 
1960). In some cases, especially in AIDS patients, these effects force discontinuation of 
therapy, leading to an almost inevitable relapse which frequently will not respond to 
the same therapy again (Haverkos, 1987; Wanke et al., 1987). Thus, there is an urgent 
need for alternative safer therapy for this disease. 
Spiramycin is a macrolide antibiotic derived from Streptomyces ambofaciens with an 
antibacterial activity comparable to that of erythromycin (Ravina et al., 1956). Early 
studies showed that spiramycin had some actiY\ty against toxoplasmosis in mice and 
rabbits (Bogacz, 1956; Garin & Eyles, 1958; MasBakal & In't Veld, 1965). Since then, 
spiramycin has been used in many countries for the treatment of human toxoplasmosis 
without showing any evidence of harmful effects on fetal development or toxicity. We 
review here the results of in-vitro, experimental and clinical investigations which have 
been performed with this compound. 
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Animal models of toxoplasmosis 
Murine models 
In mice, the RH, BK and Beverley strains of T. gondii have been used. These strains 
differ in their virulence to mice, the RH being known as especially virulent (Sabin, 
1941). However, murine susceptibility depends not only on the parasitic strain, but 
also on the strain of mouse. 
Acute toxoplasmosis. In mice, a lethal acute toxoplasmosis is produced by 
inoculation of tachyzoites of a virulent strain. After intraperitoneal challenge, the 
experimental disease is characterized by the development of a disseminated infection 
and the production of ascites containing numerous tachyzoites. The activity of a drug 
is assessed by its ability to permit the survival of treated infected mice after a given 
observation time. When no parasites are seen at autopsy in the surviving animals, their 
organs are ground in a mortar and portions of these suspensions are injected into new 
mice. The donors are considered cured when the recipient mice survive a defined 
number of days after the subinoculation and show no toxoplasma at autopsy. 
Table I summarizes results obtained after various treatments of spiramycin. In the 
preliminary studies of Bogacz (1956) the parasite inocula were not standardized before 
the inoculation of the mice, so that it is not possible to correlate the number of 
parasites inoculated with the respective antibiotic dose affording protection. Later 
spiramycin therapy protecting all infected mice was obtained in animals challenged 
with low inocula (500 tachyzoites or less) and treated with at least 8 mg of spiramycin 
per day for 14 or 28 days (Bonaduce, 1960; Mas Bakal & Int' Veld, 1965; Garin & 
Paillard, 1984). However, when more stringent experimental conditions were used, the 
authors were not able to protect 100% of the infected animals with spiramycin. 
Dealing with pregnant mice, Nguyen & Stadtsbaeder (1975), showed some 
beneficial therapeutic effect of spiramycin with regard to successful delivery, offspring 
survival and anti toxoplasma antibody assays in the offspring, but the combination of 
trimethoprim-sulphamethoxazole performed better in the same model. In addition 
Beverley et al. (1973) showed that spiramycin (2-10 mg daily for five days each week 
over four weeks) was effective in preventing the development of pathological changes 
during the early weeks of life in murine litters with experimental congenital 
toxoplasma infections. 
Chronic toxoplasmosis. Some investigations have been carried out with the Beverley 
strain of T. gondii, which is less virulent to mice showing a large number of cysts in the 
brains in chronic stage. Compared to control animals, high doses of spiramycin (13 mg 
daily for 21 days) considerably prolonged the survival period of mice, but showed only 
slight killing effects on toxoplasma (Nakayama & Matsubayashi, 1963). 
Experimental induced toxoplasmic uveitis in rabbits 
A series of experiments using spiramycin for treating induced toxoplasma anterior 
uveitis in rabbits showed that this antibiotic was effective and nontoxic with regard to 
the treatment of inflammation (Giles, Jacobs & Melton, 1964). 
Acute toxoplasmosis in squirrel monkeys 
A fatal systemic disease was produced in squirrel monkeys by oral inoculation of a 
brain suspension made from mice infected with the Beverley strain of T. gondii (Harper, 
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Table I. Studies on the activity of spiramycin against acute toxoplasmosis in mice 
T. gondii challenge Therapy Results (%) Reference 
inoculum dose duration survival cure 
strain (x 102) route (mgjday) route (days) rate rate 
U U ip 5 sc 8 0 0 Bogacz (1956) 
U ip 7·5 sc 8 100 66 
U ip 10 sc 8 100 100 
RH 200 ip 2 sc 14 30 0 Garin & 
200 ip 4 sc 14 80 40 Eyles (1958) 
200 ip 8 sc 14 80 80 
200 ip 16 sc 14 20 20 
200 sc 8+4 sc 17+8 87 100 
50 ip 4+8 sc 8+ 13 25 100 
100 lp 12+8 sc 1+16 62 20 
BK 200 ip 10 sc 7 0 0 Bonaduce (1960) 
20 lp 10 sc 7 40 ND 
2 ip 10 sc 7 100 100 
RH 100-250 ip 8 po 21 26 18 Nakayama & 
100-250 ip 13 po 21 48 26 Matsubayashi 
(1963) 
RH I ip 8 sc 14a 80 12 Mas Bakal & 
1 ip 8 sc 28a 100 100 In't Veld (1965) 
RH 5 ip 16 sc 14 100 50 Garin & 
Paillard (1984) 
RH 50 ip 7·5 po sa 50 59 Chang & 
Pechere 
(1987) 
All these experiments have been conducted with different strains of white mice weighing 20-30 g. 
Treatment was started 2-3 h after challenge except otherwise specified. 
ip, Intraperitoneal; sc, subcutaneous; po, per oral. 
a 24 h after challenge. 
ND, Not determined. 
U, Unknown. 
London & Sever, 1985). Spiramycin was not able to keep the animals from dying. 
Furthermore, sulphonamides alone or in combinations with pyrimethamine or 
trimethoprim were significantly more effective than spiramycin in treating 
toxoplasmosis in this model. 
In-vitro models of toxoplasma infection 
T. gondii is an obligate intracellular protozoan which can be cultivated in most 
mammalian cells. A few experiments have assessed the activity of spiramycin against 
intracellular T. gondii. Endpoints of these experiments included primarily light 
microscopy studies determining the number of infected cells, the number of 
toxoplasma per vacuole and the number of rosette (i.e. eight or more toxoplasma 
within a single vacuole) containing cells (Nguyen & Stadtsbaeder, 1975; Kieng Truong 
et al., 1970; Chang & Pechere, 1988). Other investigations (Chang & Pechere, 1988) 
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have measured the antitoxoplasmic activity of spiramycin by incorporation of tritiated 
uracil, a compound which is metabolized by the intracellular parasite but not by the 
host cell. In addition, the viability of the parasites remaining after antibiotic exposure 
has been tested by passaging them into a non professional phagocytic cell line (HeLa 
cells). 
All these in-vitro studies yielded the same conclusions. Spiramycin demonstrated 
antitoxoplasmic activity at relatively high concentrations. For instance, the 
concentration inhibiting 50% (ICso) of the metabolic activity of intracellular T. gondii 
has been calculated at 218 mg/1. (Chang & Pechere, 1988). Moreover, the viability test 
showed that spiramycin had no killing effect when tested at concentrations up to four 
times the ICgo . 
Clinical studies 
Spiramycin has been used in many countries for over 27 years. Surprisingly, very few 
investigations have been directed to assess the actual efficacy of spiramycin in human 
toxoplasmosis. There are only two published series concerning congential 
toxoplasmosis (Desmonts & Couvreur, 1974, 1979). Additional data from the same 
centre are presented in this volume (Couvreur, Desmonts & Thulliez, 1988). Acute 
toxoplasma infection acquired during pregnancy may result in congenital infection. 
This risk has been evaluated at 15% in the first trimester, 30% in the second trimester 
and 60% in the third trimester. However, only the toxoplasmic infection acquired 
during the first trimester of pregnancy has been associated with severe congenital 
infection. There seems to be a lag period between the maternal and the fetal infection. 
An antitoxoplasmic treatment is recommended in the hope of preventing the 
congenital infection provided the diagnosis is made early enough. In this perspective 
three-week courses of oral spiramycin, alternated with two weeks of no treatment until 
term, have reduced the incidence of congenital infection from 17% to 5% and from 
61 % to 23% (Desmonts & Couvreur, 1974, 1979). 
Patients having active toxoplasmic chorioretinitis must receive specific drug therapy. 
Chodos & Habegger-Chodos (1961) showed that in a series of 67 patients spiramycin 
was an effective agent for use in posterior uveitis presumably caused by toxoplasma. 
Fajardo, Furguiele & Leopold (1962) reported a series of 87 patients who had received 
either spiramycin and steroids, sulphadiazine and pyrimethamine and steroids or 
steroids therapy alone. They found that although spiramycin therapy resulted in 
quiescence of posterior uveitis, the combination of sulphadiazine and pyrimethamine 
was more effective. Cassidy, Bahler & Minken (1964) and Canamucio, Hallet & 
Leopold (1963) reported failures of spiramycin for treating toxoplasmic uveitis. Timsit 
& Bloch-Michel, (1987) reported that, in a series of 54 patients diagnosed as having 
active toxoplasmosis chorioretinitis, the combination of pyrimethamine and 
sulphadiazine seemed statistically more active than other reported treatments, 
including therapy with systemic steroids alone or in combination with spiramycin. 
Discussion 
The antitoxoplasma activity of spiramycin is supported by converging lines of evidence 
provided by in-vitro, experimental and clinical studies. Protection of animals from 
lethal experimental toxoplasmosis within the relatively short time of observation (up to 
one month), and blockade of the nucleotide synthesis of intracellular parasites shown by 
uracil incorporation studies indicate essentially an inhibitory effect. Moreover, the 
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killing effect of spiramycin against T. gondii remains limited as suggested by the in-
vitro viability tests and determination of the cure rate in the mouse experiments. Since 
T. gondii is a eukaryotic cell and spiramycin a macrolide, this activity is somewhat 
surprising. Early studies have demonstrated that erythromycin inhibits bacterial 
protein synthesis by binding to the 50S ribosomal unit, which prevents elongation of 
the peptide chain (Pestka, 1977). Spiramycin (and probably all macrolides) act 
similarly (Menninger & Otto, 1982). Erythromycin does not bind to mammalian 80S 
ribosomes, and this accounts in -part for -its selective toxicity (Mao, Putterman & 
Wiegand, 1970). Therefore, in order to explain the activity of spiramycin against 
T. gondii we have to admit one of the two following hypotheses. (i) Spiramycin may 
interact with the parasite ribosome, as it does with bacteria. However, fractionation of 
RNA extracted from T. gondii by sedimentation revealed the presence of three major 
RNA components sedimenting at 24S, 19S and 4S to 5S (Remington et al., 1970), a 
pattern different from that obtained with bacteria. So, in order to prove this hypothesis 
a macrolide binding site will have to be demonstrated in the ribosomal components of 
T. gondii. (ii) Spiramycin may have a non ribosomal mode of action. Among the 
possibilities here, an immuno-modulating effect of spiramycin should be investigated. 
Compared with spiramycin, various clinical studies indicate that the combination of 
pyrimethamine and sulphadiazine is more toxic but more effective for treating severe 
cases of toxoplasmosis. Thus, spiramycin should be reserved for the treatment of 
toxoplasmosis when toxicity is particularly unacceptable. This might be the case during 
pregnancy, for the prevention of congenital toxoplasmosis or in some cases of acute 
toxoplasmosis in non pregnant patients with normal immune defences, for instance 
when a prolonged high fever occurs. 
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